Scilex Holding Company Payments of Stock Issuance Costs
Scilex Holding Company (SCLX) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-04-10
- Scilex Holding Company payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company payments of stock issuance costs for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company payments of stock issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Scilex Holding Company payments of stock issuance costs for fiscal 2024 was $4.37M.
- Scilex Holding Company payments of stock issuance costs for fiscal 2023 was $0.00.
- Scilex Holding Company payments of stock issuance costs for fiscal 2021 was $416.26K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 7 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 10 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $0.00 derived: sum of 2 quarters · filed 2026-04-10 | $0.00 derived: sum of 3 quarters · filed 2026-04-10 | $0.00 10-K · filed 2026-04-10 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $1.53M derived: sum of 4 quarters · filed 2026-04-10 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $1.53M derived: sum of 3 quarters · filed 2026-04-10 | $1.54M derived: sum of 4 quarters · filed 2026-04-10 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $1.53M derived: sum of 2 quarters · filed 2026-04-10 | $1.54M derived: sum of 3 quarters · filed 2026-04-10 | $3.09M derived: sum of 4 quarters · filed 2026-04-10 | ||
| 2024-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $1.54M derived: sum of 2 quarters · filed 2026-04-10 | $3.09M derived: sum of 3 quarters · filed 2026-04-10 | $4.37M 10-K · filed 2026-04-10 | ||
| 2024-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.57M derived: sum of 2 quarters · filed 2025-11-14 | $2.84M 10-Q · filed 2025-11-14 | $2.84M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.83M 10-Q · filed 2025-08-13 | $2.83M derived: sum of 3 quarters · filed 2025-08-13 | $2.83M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $1.28M 10-Q · filed 2025-05-14 | $1.28M derived: sum of 2 quarters · filed 2025-05-14 | $1.28M derived: sum of 3 quarters · filed 2025-05-14 | $1.28M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $0.00 derived: sum of 2 quarters · filed 2025-01-17 | $0.00 10-Q · filed 2025-01-17 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $416.26K derived: sum of 3 quarters · filed 2022-11-04 | $416.26K 10-K · filed 2022-02-24 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $416.26K derived: sum of 2 quarters · filed 2022-11-04 | $416.26K 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | $416.26K 10-Q/A · filed 2021-08-24 | $416.26K 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | $416.26K 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | $118.21K 10-K · filed 2022-02-24 | |||||
| 2020-09-30 | $70.28K 10-Q/A · filed 2021-12-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |